Citations (97)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Sung-Nan Pei & Chien-Hung Chen. (2015) Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab. Leukemia & Lymphoma 56:6, pages 1611-1618.
Read now
Read now
Judit Rubio, Fernando Franco, Antonio Sánchez, Blanca Cantos, Miriam Méndez, Virginia Calvo, Constanza Maximiano, David Perez, Isabel Millán, Margarita Sánchez-Beato & Mariano Provencio. (2015) Does the presence of hepatitis virus B and C influence the evolution of diffuse large B-cell lymphoma?. Leukemia & Lymphoma 56:6, pages 1686-1690.
Read now
Read now
Mauro Viganò, Giampaolo Mangia & Pietro Lampertico. (2014) Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy. Expert Opinion on Biological Therapy 14:7, pages 1019-1031.
Read now
Read now
Jeffrey Bryan & Gautam Borthakur. (2011) Role of rituximab in first-line treatment of chronic lymphocytic leukemia. Therapeutics and Clinical Risk Management 7, pages 1-11.
Read now
Read now
Xing Li, Qu Lin, Min Dong, Jing-Yun Wen, Li Wei, Xiao-Kun Ma, Zhan-Hong Chen & Xiang-Yuan Wu. (2010) Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma. Leukemia & Lymphoma 51:9, pages 1678-1685.
Read now
Read now
Ron Ram, Isaac Ben-Bassat, Ofer Shpilberg, Aaron Polliack & Pia Raanani. (2009) The late adverse events of rituximab therapy – rare but there!. Leukemia & Lymphoma 50:7, pages 1083-1095.
Read now
Read now
Timucin Cil, Abdullah Altintas, Yekta Tuzun, Semir Pasa & Abdurrahman Isikdogan. (2007) Hepatitis B virus reactivation induced by Yttrium-90-ibritumomab-tiuxetan. Leukemia & Lymphoma 48:9, pages 1866-1868.
Read now
Read now
Sercan Aksoy, Hakan Harputluoglu, Saadettin Kilickap, Didem Sener Dede, Omer Dizdar, Kadri Altundag & Ibrahim Barista. (2007) Rituximab-related viral infections in lymphoma patients. Leukemia & Lymphoma 48:7, pages 1307-1312.
Read now
Read now
Anjum S. Kaka, Cliona M. Rooney & Barbara Savoldo. (2007) What influence has B-cell depletion on viral infections?. Leukemia & Lymphoma 48:7, pages 1257-1258.
Read now
Read now
Bertrand Coiffier. (2006) Hepatitis B Virus Reactivation in Patients Receiving Chemotherapy for Cancer Treatment: Role of Lamivudine Prophylaxis. Cancer Investigation 24:5, pages 548-552.
Read now
Read now
Articles from other publishers (87)
Tejas S. Athni & Sara Barmettler. (2023) Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab. Annals of Allergy, Asthma & Immunology 130:6, pages 699-712.
Crossref
Crossref
Betül ERSÖZ ACAR. (2022) İmmünsüpresif ilaçlar ve HBV reaktivasyonu. Bolu Abant Izzet Baysal Universitesi Tip Fakultesi Abant Tip Dergisi.
Crossref
Crossref
Paniz Shirmast, Mahdi Abedinzade Shahri, Salar Pashangzadeh, Hessam Mirshahabi, Elham Samadi & Nima Motamed. (2022) Detection of occult hepatitis B virus in patients undergoing chemotherapy in Iran. Future Virology 17:1, pages 29-36.
Crossref
Crossref
Stijn J De Keukeleire, Tijl Vermassen, Zahra M Nezhad, Tessa Kerre, Vibeke Kruse, Hans Van Vlierberghe, Karim Vermaelen & Sylvie Rottey. (2021) Managing viral hepatitis in cancer patients under immune checkpoint inhibitors: should we take the risk?. Immunotherapy 13:5, pages 409-418.
Crossref
Crossref
Lu Han, Jian Zhou, Keshu Zhou, Xinghu Zhu, Lingdi Zhao, Baijun Fang, Qingsong Yin, Xudong Wei, Hu Zhou, Linlin Li, Bengling Xu, Jishuai Zhang, Yongping Song & Quanli Gao. (2020) Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus. Journal for ImmunoTherapy of Cancer 8:2, pages e000927.
Crossref
Crossref
Toshiyuki Watanabe, Jun Fukae, Shinji Fukaya, Norifumi Sawamukai, Masato Isobe, Megumi Matsuhashi, Masato Shimizu, Kazumasa Akikawa, Kazuhide Tanimura, Tatsuya Atsumi & Takao Koike. (2018) Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease‐modifying antirheumatic drugs. International Journal of Rheumatic Diseases 22:4, pages 574-582.
Crossref
Crossref
Robert A. Mitchell, Trana Hussaini, Alan H. Yau, Mel Krajden, Alissa J. Wright, Charles H. Scudamore, Vladimir Marquez Azalgara, Siegfried R. Erb & Eric M. Yoshida. (2018) Transplantation of a Liver Allograft From a Hepatitis C Virus Seropositive Donor With Previous Sustained Virologic Response to an Uninfected Recipient Suffering Steroid Refractory Acute Graft Rejection With No Evidence of HCV Transmission. Transplantation Direct 4:3, pages e347.
Crossref
Crossref
Seong Jae YeoHyun Seok LeeByung Ik JangEun Soo KimSeong Woo JeonSung Kook KimKyeong Ok KimYoo Jin LeeHyun Jik LeeKyung Sik ParkYun Jin JungEun Young KimChang Heon Yang. (2018) Nonimmunity against hepatitis B virus infection in patients newly diagnosed with inflammatory bowel disease. Intestinal Research 16:3, pages 400.
Crossref
Crossref
Ahmet Taner Sümbül & Özgür Özyılkan. 2018. The MASCC Textbook of Cancer Supportive Care and Survivorship. The MASCC Textbook of Cancer Supportive Care and Survivorship
445
465
.
Kali Zhou & Norah Terrault. (2017) Management of hepatitis B in special populations. Best Practice & Research Clinical Gastroenterology 31:3, pages 311-320.
Crossref
Crossref
Dafan Chen, Shengzheng Luo, Qiwen Ben, Lungen Lu, Xinjian Wan & Jianjiong Wu. (2017) Prevalence of hepatitis B and C and factors for infection and nonimmune in inflammatory bowel disease patients in China. European Journal of Gastroenterology & Hepatology 29:5, pages 509-515.
Crossref
Crossref
Venessa Pattullo. (2016) Prevention of Hepatitis B reactivation in the setting of immunosuppression. Clinical and Molecular Hepatology 22:2, pages 219-237.
Crossref
Crossref
L. Mozessohn, K. K. W. Chan, J. J. Feld & L. K. Hicks. (2015) Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis. Journal of Viral Hepatitis 22:10, pages 842-849.
Crossref
Crossref
Shujun Ma. (2015) Research advances in reactivation of hepatitis virus after chemotherapy for non-Hodgkin’s lymphoma-combined hepatitis B virus infection. Infection International 4:3, pages 75-80.
Crossref
Crossref
Samir DaliaYaman SuleimanDavid W. CroyLubomir Sokol. (2015) Association of Lymphomagenesis and the Reactivation of Hepatitis B Virus in Non-Hodgkin Lymphoma. Cancer Control 22:3, pages 360-365.
Crossref
Crossref
Venessa Pattullo. (2015) Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure. World Journal of Hepatology 7:7, pages 954.
Crossref
Crossref
María Luisa Gutiérrez García, Sonia Alonso Lopez, María Dolores Martín Rios, Patricia Sanmartin Fenollera, Sandra Agudo Fernandez & Conrado Manuel Fernández Rodriguez. (2015) Reactivación del virus de la hepatitis B en pacientes tratados con rituximab: incidencia y factores de riesgo. Gastroenterología y Hepatología 38:1, pages 1-6.
Crossref
Crossref
Fan Yang, Huan-Ling Zhu, Chuan He, Jian-Jun Li, Bing Xiang, Xu Cui, Jie Huang, Jie Ji, Hong-Bing Ma & Ting Liu. (2012) Effect of Antiviral Prophylaxis Strategy for Chemotherapy-Associated Hepatitis B Reactivation in Non-Hodgkin’s Lymphoma Patients with Hepatitis B Virus Infection: A Retrospective Cohort Study. Indian Journal of Hematology and Blood Transfusion 30:2, pages 97-104.
Crossref
Crossref
Mei Lan Huang, Xi Tao Xu, Jun Shen, Yu Qi Qiao, Zhang Han Dai & Zhi Hua Ran. (2014) Prevalence and factors related to hepatitis B and C infection in inflammatory bowel disease patients in China: A retrospective study. Journal of Crohn's and Colitis 8:4, pages 282-287.
Crossref
Crossref
Noboru Shinkai, Kentaro Matsuura, Fuminaka Sugauchi, Tsunamasa Watanabe, Shuko Murakami, Etsuko Iio, Shintaro Ogawa, Shunsuke Nojiri, Takashi Joh & Yasuhito Tanaka. (2013) Application of a Newly Developed High-Sensitivity HBsAg Chemiluminescent Enzyme Immunoassay for Hepatitis B Patients with HBsAg Seroclearance. Journal of Clinical Microbiology 51:11, pages 3484-3491.
Crossref
Crossref
Irit Avivi, Dina Stroopinsky & Tamar Katz. (2013) Anti-CD20 monoclonal antibodies: Beyond B-cells. Blood Reviews 27:5, pages 217-223.
Crossref
Crossref
Yi-Hsiang HuangLiang-Tsai HsiaoYing-Chung HongTzeon-Jye ChiouYuan-Bin YuJyh-Pyng GauChun-Yu LiuMuh-Hwa YangCheng-Hwai TzengPui-Ching LeeHan-Chieh LinShou-Dong Lee. (2013) Randomized Controlled Trial of Entecavir Prophylaxis for Rituximab-Associated Hepatitis B Virus Reactivation in Patients With Lymphoma and Resolved Hepatitis B. Journal of Clinical Oncology 31:22, pages 2765-2772.
Crossref
Crossref
Chun-Jen Liu, Pei-Jer Chen, Ding-Shinn Chen & Jia-Horng Kao. (2011) Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. Hepatology International 7:2, pages 316-326.
Crossref
Crossref
Ferruccio Bonino & Maurizia Rossana Brunetto. (2013) Occult Hepatitis B Virus (HBV) Infections: Hepatitis B Surface Antigen (HBsAg) Negative and Primary Occult. Current Hepatitis Reports 12:2, pages 112-118.
Crossref
Crossref
F. Morisco, F. Castiglione, A. Rispo, T. Stroffolini, S. Sansone, R. Vitale, M. Guarino, L. Biancone, A. Caruso, R. D'Inca, R. Marmo, A. Orlando, G. Riegler, L. Donnarumma, S. Camera, F. Zorzi, S. Renna, V. Bove, G. Tontini, M. Vecchi & N. Caporaso. (2012)
Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis
B
or
C
virus infection
. Journal of Viral Hepatitis 20:3, pages 200-208.
Crossref
Crossref
Myung Jin OhHeon Ju Lee. (2013) A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experience. Clinical and Molecular Hepatology 19:1, pages 51.
Crossref
Crossref
Jessica P. Hwang, John M. Vierling, Andrew D. Zelenetz, Susan C. Lackey & Rohit Loomba. (2012) Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Supportive Care in Cancer 20:11, pages 2999-3008.
Crossref
Crossref
Yi-Hsiang Huang, Han-Chieh Lin & Shou-Dong Lee. (2012) Management of chemotherapy-induced hepatitis B virus reactivation. Journal of the Chinese Medical Association 75:8, pages 359-362.
Crossref
Crossref
Yasunori Fujimoto, Naoya Hashimoto, Manabu Kinoshita, Yuko Miyazaki, Satoshi Tanaka, Takayuki Yakushijin, Tetsuo Takehara, Naoki Kagawa & Toshiki Yoshimine. (2011) Hepatitis B virus reactivation associated with temozolomide for malignant glioma: a case report and recommendation for prophylaxis. International Journal of Clinical Oncology 17:3, pages 290-293.
Crossref
Crossref
Daniela Francisci, Flavio Falcinelli, Elisabetta Schiaroli, Monia Capponi, Barbara Belfiori, Enisia Cecchini & Franco Baldelli. (2018) Reactivation of Hepatitis B Virus Replication Due to Cytotoxic Therapy: A Five-Year Prospective Study. Tumori Journal 98:2, pages 220-224.
Crossref
Crossref
Harrys A. Torres & Marta Davila. (2012) Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nature Reviews Clinical Oncology 9:3, pages 156-166.
Crossref
Crossref
Panagiotis Papamichalis, Alexis Alexiou, Maria Boulbou, George N. Dalekos & Eirini I. Rigopoulou. (2012) Reactivation of resolved hepatitis B virus infection after immunosuppression: Is it time to adopt pre-emptive therapy?. Clinics and Research in Hepatology and Gastroenterology 36:1, pages 84-93.
Crossref
Crossref
MASARU KATO, TATSUYA ATSUMI, TAKASHI KURITA, TOSHIO ODANI, YUICHIRO FUJIEDA, KOTARO OTOMO, TETSUYA HORITA, SHINSUKE YASUDA & TAKAO KOIKE. (2011) Hepatitis B Virus Reactivation by Immunosuppressive Therapy in Patients with Autoimmune Diseases: Risk Analysis in Hepatitis B Surface Antigen-negative Cases. The Journal of Rheumatology 38:10, pages 2209-2214.
Crossref
Crossref
Saulat Mushtaq, Susan M Goodman & Carla R Scanzello. (2011) Perioperative Management of Biologic Agents Used in Treatment of Rheumatoid Arthritis. American Journal of Therapeutics 18:5, pages 426-434.
Crossref
Crossref
A.M. Evens, B.D. Jovanovic, Y.-C. Su, D.W. Raisch, D. Ganger, S.M. Belknap, M.-S. Dai, B.-C. C. Chiu, B. Fintel, Y. Cheng, S.-S. Chuang, M.-Y. Lee, T.-Y. Chen, S.-F. Lin & C.-Y. Kuo. (2011) Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Annals of Oncology 22:5, pages 1170-1180.
Crossref
Crossref
J. P. Gisbert, M. Chaparro & M. Esteve. (2011) Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 33:6, pages 619-633.
Crossref
Crossref
Theodoros Kelesidis, George Daikos, Dimitrios Boumpas & Sotirios Tsiodras. (2011) Does rituximab increase the incidence of infectious complications? A narrative review. International Journal of Infectious Diseases 15:1, pages e2-e16.
Crossref
Crossref
Filomena Morisco, Fabiana Castiglione, Antonio Rispo, Tommaso Stroffolini, Roberto Vitale, Stefano Sansone, Rocco Granata, Ambrogio Orlando, Riccardo Marmo, Gabriele Riegler, Maurizio Vecchi, Livia Biancone & Nicola Caporaso. (2011) Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease. Digestive and Liver Disease 43, pages S40-S48.
Crossref
Crossref
Marta Davila & Harrys A. Torres. 2011. Principles and Practice of Cancer Infectious Diseases. Principles and Practice of Cancer Infectious Diseases
189
194
.
Donald M. Arnold, Mark A. Crowther, Ralph M. Meyer, Julie Carruthers, Julie DiTomasso, Nancy M. Heddle, Anne McLeod & John G. Kelton. (2010) Misleading hepatitis B test results due to intravenous immunoglobulin administration: implications for a clinical trial of rituximab in immune thrombocytopenia. Transfusion 50:12, pages 2577-2581.
Crossref
Crossref
A. Nath, R. Agarwal, P. Malhotra & S. Varma. (2010) Prevalence of hepatitis B virus infection in non‐Hodgkin lymphoma: a systematic review and meta‐analysis. Internal Medicine Journal 40:9, pages 633-641.
Crossref
Crossref
John S Lubel & Peter W Angus. (2010) Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: Diagnosis and management. Journal of Gastroenterology and Hepatology 25:5, pages 864-871.
Crossref
Crossref
Eduardo Muñoz Bertrán, Elena Pérez Ceballos, Rosa Gómez Espín & Isabel Ortega González. (2010) Reactivación de la hepatitis B en un paciente HBsAg negativo/antiHBc positivo con linfoma B que recibió quimioterapia con rituximab. Gastroenterología y Hepatología 33:5, pages 377-381.
Crossref
Crossref
Samantha M. Jaglowski & John C. Byrd. (2010) Rituximab in Chronic Lymphocytic Leukemia. Seminars in Hematology 47:2, pages 156-169.
Crossref
Crossref
Juan C. Gea-Banacloche. (2010) Rituximab-Associated Infections. Seminars in Hematology 47:2, pages 187-198.
Crossref
Crossref
I-Cheng Lee, Yi-Hsiang Huang, Chi-Jen Chu, Pui-Ching Lee, Han-Chieh Lin & Shou-Dong Lee. (2010) Hepatitis B Virus Reactivation After 23 Months of Rituximab-based Chemotherapy in an HBsAg-negative, Anti-HBs-positive Patient With Follicular Lymphoma. Journal of the Chinese Medical Association 73:3, pages 156-160.
Crossref
Crossref
Wing-I. Cheung, Henry Lik-Yuen Chan, Vincent King-Sun Leung, Chi-Hang Tse, Kitty Fung, Shek-Ying Lin, Ann Wong, Vincent Wai-Sun Wong & Tai-Nin Chau. (2010) Reactivation of hepatitis B virus infection with persistently negative HBsAg on three HBsAg assays in a lymphoma patient undergoing chemotherapy. Journal of Clinical Virology 47:2, pages 193-195.
Crossref
Crossref
Ahmet Taner Sümbül & Özgür Özyilkan. 2011. The MASCC Textbook of Cancer Supportive Care and Survivorship. The MASCC Textbook of Cancer Supportive Care and Survivorship
267
278
.
Mayra J. Sanchez, Maria Buti, Maria Homs, Andres Palacios, Francisco Rodriguez-Frias & Rafael Esteban. (2009) Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab. Journal of Hepatology 51:6, pages 1091-1096.
Crossref
Crossref
Tara N. Palmore, Neeral L. Shah, Rohit Loomba, Brian B. Borg, Uri Lopatin, Jordan J. Feld, Farooq Khokhar, Glen Lutchman, David E. Kleiner, Neal S. Young, Richard Childs, A. John Barrett, T. Jake Liang, Jay H. Hoofnagle & Theo Heller. (2009) Reactivation of Hepatitis B With Reappearance of Hepatitis B Surface Antigen After Chemotherapy and Immunosuppression. Clinical Gastroenterology and Hepatology 7:10, pages 1130-1137.
Crossref
Crossref
Jacob Laubach. (2009) Progressive Multifocal Leukoencephalopathy After Therapy for Chronic Lymphocytic Leukemia. Clinical Leukemia 3:2, pages E24-E26.
Crossref
Crossref
Winnie Yeo. (2009) Hepatitis B virus reactivation in association with antineoplastic therapy. Current Hepatitis Reports 8:3, pages 127-133.
Crossref
Crossref
Jan Gossmann, Ernst-Heinrich Scheuermann, Heinz-Georg Kachel, Helmut Geiger & Ingeborg A. Hauser. (2009) Reactivation of hepatitis B two years after rituximab therapy in a renal transplant patient with recurrent focal segmental glomerulosclerosis: a note of caution. Clinical Transplantation 23:3, pages 431-434.
Crossref
Crossref
Jia-Min Wu, Yi-Hsiang Huang, Pui-Ching Lee, Han-Chieh Lin & Shou-Dong Lee. (2009) Fatal Reactivation of Hepatitis B Virus in a Patient Who Was Hepatitis B Surface Antigen Negative and Core Antibody Positive Before Receiving Chemotherapy for Non-Hodgkin Lymphoma. Journal of Clinical Gastroenterology 43:5, pages 496-498.
Crossref
Crossref
Rosa Pérez-Grande, Nieves Gutiérrez-Zufiaurre, Santiago Muñoz-Criado, Ana M. Blázquez de Castro, Lourdes Vázquez López, Francisco González San Martín, Jose Angel García Rodríguez & Juan Luis Muñoz Bellido. (2009) Hepatitis B reactivation in a hepatitis B surface antigen-negative patient after allogeneic bone marrow transplant: successful treatment with lamivudine and seroconversion. Diagnostic Microbiology and Infectious Disease 64:1, pages 80-82.
Crossref
Crossref
Jay H. Hoofnagle. (2009) Reactivation of hepatitis B. Hepatology 49:S5, pages S156-S165.
Crossref
Crossref
Raymond Liang. (2009) How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 113:14, pages 3147-3153.
Crossref
Crossref
Jeanne McCarthy & Ajay K. Gopal. (2009) Successful Use of Full-Dose Dexamethasone, High-Dose Cytarabine, and Cisplatin as Part of Initial Therapy in Non-Hodgkin and Hodgkin Lymphoma with Severe Hepatic Dysfunction. Clinical Lymphoma and Myeloma 9:2, pages 167-170.
Crossref
Crossref
Winnie YeoTung C. ChanNancy W.Y. LeungWai Y. LamFrankie K.F. MoMiu Ting ChuHenry L.Y. ChanEdwin P. HuiKenny I.K. LeiTony S.K. MokPaul K.S. Chan. (2009) Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab. Journal of Clinical Oncology 27:4, pages 605-611.
Crossref
Crossref
Ersan Ozaslan & Tugrul Purnak. (2009) Controversies about occult hepatitis B virus infection. World Journal of Gastroenterology 15:39, pages 4986.
Crossref
Crossref
Carme Loras, Cristina Saro, Ferràn Gonzalez-Huix, Miguel Mínguez, Olga Merino, Javier P Gisbert, Jesús Barrio, Antonio Bernal, Ana Gutiérrez, Marta Piqueras, Xavier Calvet, Montserrat Andreu, Agueda Abad, Daniel Ginard, Luis Bujanda, Julián Panés, Miquel Torres, Fernando Fernández-Bañares, Josep M Viver & Maria Esteve. (2008) Prevalence and Factors Related to Hepatitis B and C in Inflammatory Bowel Disease Patients in Spain: A Nationwide, Multicenter Study. The American Journal of Gastroenterology 104:1, pages 57-63.
Crossref
Crossref
Halim Charbel & James H. Lewis. 2010. Chronic Viral Hepatitis. Chronic Viral Hepatitis
307
336
.
Yu Xuan Koo, Daniel S. W. Tan, Iain B. Tan, Miriam Tao, Wan Cheng Chow & Soon Thye Lim. (2009) Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy. Cancer, pages NA-NA.
Crossref
Crossref
Masami Miyagawa, Masahito Minami, Kota Fujii, Rei Sendo, Kojiro Mori, Daisuke Shimizu, Tomoaki Nakajima, Kohichiroh Yasui, Yoshito Itoh, Masafumi Taniwaki, Takeshi Okanoue & Toshikazu Yoshikawa. (2008) Molecular characterization of a variant virus that caused de novo hepatitis B without elevation of hepatitis B surface antigen after chemotherapy with rituximab. Journal of Medical Virology 80:12, pages 2069-2078.
Crossref
Crossref
Eiji Tanaka & Takeji Umemura. (2008) History and prevention of de novo hepatitis B virus-related hepatitis in Japan and the world. Clinical Journal of Gastroenterology 1:3, pages 83-86.
Crossref
Crossref
Takeji Umemura, Eiji Tanaka, Kendo Kiyosawa & Hiromitsu Kumada. (2008) Mortality Secondary to Fulminant Hepatic Failure in Patients with Prior Resolution of Hepatitis B Virus Infection in Japan. Clinical Infectious Diseases 47:5, pages e52-e56.
Crossref
Crossref
Maria J. Garcia-Rodriguez, Miguel A. Canales, Dolores Hernandez-Maraver & Fernando Hernandez-Navarro. (2008) Late reactivation of resolved hepatitis B virus infection: An increasing complication post rituximab-based regimens treatment?. American Journal of Hematology 83:8, pages 673-675.
Crossref
Crossref
Manoj Kumar, Barjesh C Sharma & Shiv K Sarin. (2008) Hepatitis E virus as an etiology of acute exacerbation of previously unrecognized asymptomatic patients with hepatitis B virus-related chronic liver disease. Journal of Gastroenterology and Hepatology 23:6, pages 883-887.
Crossref
Crossref
C-H. Yang & C-T. Chiu. (2008) Chronic hepatitis B reactivation and systemic glucocorticosteroid therapy: reply from authors. British Journal of Dermatology 158:6, pages 1397-1397.
Crossref
Crossref
Stephen Barclay, Stanislas Pol, David Mutimer, Yves Benhamou, Peter R. Mills, Peter C. Hayes, Sheila Cameron & William Carman. (2008) Erratum to ‘The management of chronic hepatitis B in the immunocompromised patient: Recommendations from a single topic meeting’ [J. Clin. Virol. 41 (4) 2008 243–254]. Journal of Clinical Virology 42:1, pages 104-115.
Crossref
Crossref
Stephen Barclay, Stanislas Pol, David Mutimer, Yves Benhamou, Peter R. Mills, Peter C. Hayes, Sheila Cameron & William Cameron. (2008) The management of chronic hepatitis B in the immunocompromised patient: Recommendations from a single topic meeting. Journal of Clinical Virology 41:4, pages 243-254.
Crossref
Crossref
Takashi Maki, Angela Carville, Isaac E. Stillman, Kanetoshi Sato, Tetsuro Kodaka, Keisuke Minamimura, Norihiko Ogawa, Akira Kanamoto, Rita Gottschalk, Anthony P. Monaco, Amanda Marr-Belvin, Susan V. Westmoreland & Prabhat Sehgal. (2008) SV40 Infection Associated With Rituximab Treatment After Kidney Transplantation in Nonhuman Primates. Transplantation 85:6, pages 893-902.
Crossref
Crossref
Dina Attias & Sheila Weitzman. (2008) The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: a review of available evidence. Current Opinion in Pediatrics 20:1, pages 17-22.
Crossref
Crossref
S. Pol & A. Vallet-Pichard. (2008) Hépatite chronique B : situations rares : dialyse, transplantation rénale et traitements pré-emptifs en situation d’immunosuppression. Gastroentérologie Clinique et Biologique 32:1, pages S34-S41.
Crossref
Crossref
Amy A. Pruitt. 2008. Cancer Neurology In Clinical Practice. Cancer Neurology In Clinical Practice
353
378
.
Holbrook E. Kohrt, Daniel L. Ouyang & Emmet B. Keeffe. (2007) Antiviral Prophylaxis for Chemotherapy-Induced Reactivation of Chronic Hepatitis B Virus Infection. Clinics in Liver Disease 11:4, pages 965-991.
Crossref
Crossref
J. S. Lubel, A. G. Testro & P. W. Angus. (2007) Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Internal Medicine Journal 37:10, pages 705-712.
Crossref
Crossref
Yasser Khaled & Amr Hanbali. (2007) Hepatitis B virus reactivation in a case of Waldenstrom's macroglobulinemia treated with chemotherapy and Rituximab despite Adefovir prophylaxis. American Journal of Hematology 82:7, pages 688-688.
Crossref
Crossref
Nathalie Schnepf, Pierre Sellier, Marc Bendenoun, Jean-Marc Zini, Marie-José Sanson-le pors & Marie-Christine Mazeron. (2007) Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy. Journal of Clinical Virology 39:1, pages 48-50.
Crossref
Crossref
M. G. ChhedaJ. DrappatzN. J. GreenbergerS. KesariS. E. WeissD. C. GigasL. M. DohertyP. Y. Wen. (2007) Hepatitis B reactivation during glioblastoma treatment with temozolomide: A cautionary note. Neurology 68:12, pages 955-956.
Crossref
Crossref
Gadi Lalazar, Deborah Rund & Daniel Shouval. (2007) Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. British Journal of Haematology 136:5, pages 699-712.
Crossref
Crossref
Takeshi Terashima, Kuniaki Arai, Takuya Komura, Hiroshi Iida, Takashi Kagaya, Yoshio Sakai, Tatsuya Yamashita, Akito Sakai, Eishiro Mizukoshi, Yasunari Nakamoto, Masao Honda, Shuichi Kaneko, You Zen & Yasuni Nakanuma. (2007) A non-Hodgkin lymphoma patient with reactivation of HBV during chemotherapy and emergence of a YMDD-motif mutant on lamivudine, eventually controlled by adfovil dipovoxil. Kanzo 48:7, pages 309-316.
Crossref
Crossref
H. E. KOHRT, D. L. OUYANG & E. B. KEEFFE. (2006) Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Alimentary Pharmacology and Therapeutics 24:7, pages 1003-1016.
Crossref
Crossref
Carla R. Scanzello, Mark P. Figgie, Bryan J. Nestor & Susan M. Goodman. (2006) Perioperative Management of Medications Used in the Treatment of Rheumatoid Arthritis. HSS Journal®: The Musculoskeletal Journal of Hospital for Special Surgery 2:2, pages 141-147.
Crossref
Crossref
Justin Shah, Eric M. Yoshida, Joseph Connors & Sharlene Gill. (2006) Hepatic Dysfunction During and After Lymphoma Chemotherapy in Patients With Hepatitis C. Journal of Clinical Gastroenterology 40:7, pages 636-638.
Crossref
Crossref
Susana Vives, Juan Manuel Sancho, Ramón Planas & Josep Maria Ribera. (2006) Reactivación del virus de la hepatitis B tras cese de la profilaxis con lamivudina en una paciente con linfoma no hodgkiniano tratada con quimioterapia y rituximab. Medicina Clínica 127:1, pages 39.
Crossref
Crossref
Winnie Yeo & Philip J. Johnson. (2006) Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43:2, pages 209-220.
Crossref
Crossref